-
Achieved 22% total revenue growth in Q4 2025, driven by a 31% increase in clinical revenue as the core business re-accelerated toward historical levels.
-
Processed nearly 1 petabyte of genomic data in 2025, doubling volume from two years ago due to a market shift toward large comprehensive panels and multi-omic analysis.
-
Expanded adjusted gross margin by 140 basis points to 74.2% through a major architectural modernization that increased compute capacity tenfold and reduced whole genome analysis time to under 6 hours.
-
Secured two of the largest integrated health systems in the US, representing a combined potential of 60,000 annual genomic tests and 1 million oncology/rare disease patients.
-
Maintained high platform stickiness with annualized revenue churn below 1% and a Net Promoter Score of 67, validating the decentralized AI deployment model.
-
Announced a leadership transition with Ross Muken to become CEO in July 2026, while founder Jurgi Camblong moves to Executive Chairman to focus on technical innovation.
-
Leveraged a diverse data stream from 75 countries to launch ‘Digital Twins’ for lung cancer, enabling AI-driven virtual simulations for therapy selection.
-
Projecting 2026 revenue between $92 million and $94 million, with growth heavily back-half weighted as record 2025 bookings transition to routine usage.
-
Management anticipates a net positive biopharma contribution in 2026 as their story begins to resonate with senior members of top 20 pharmaceutical companies, though they are not yet forecasting a dramatic acceleration or ‘hockey stick’ growth for that year.
-
Targeting adjusted EBITDA breakeven by the end of 2026 and positive adjusted EBITDA in the second half of 2027 by dropping 60% of incremental revenue to the bottom line.
-
Assuming continued ASP expansion as customers migrate to higher-value products like MSK-ACCESS and Enhanced Exomes, despite lower-ASP volume growth in emerging markets.
-
Planning to hold operating expenses flat in local currency by flattening organizational structures and optimizing discretionary spending.
-
Reported significant adverse foreign exchange impacts due to a 14% appreciation of the Swiss franc, which inflated payroll and rent expenses in US dollar terms.
-
Incurred $1.8 million in legal expenses related to patent litigation with Guardant Health; however, the Unified Patent Court recently rejected Guardant’s request for provisional measures.
-
Strengthened liquidity by raising $15.5 million through an ATM facility and expanding a credit facility with Perceptive Advisors by $25 million.
-
Identified a record low net dollar retention of 115%, up from 104% in the prior year, driven by successful cross-selling of additional clinical applications.
